Literature DB >> 25714510

The development of a recombinant hepatitis E vaccine HEV 239.

Shao-Wei Li1, Qinjian Zhao, Ting Wu, Shu Chen, Jun Zhang, Ning-Shao Xia.   

Abstract

Hepatitis E virus (HEV) infection is one of the main causes of acute hepatitis worldwide. A recombinant hepatitis E vaccine, HEV 239, has been licensed in China for immunizing adults of 16 y old and above. The vaccine antigen contains pORF2 aa 368 - 606 of the HEV genotype 1 expressed in E. coli. The quality of the vaccine is controlled through a combination of biophysical, biochemical and immunochemical methods. The vaccine is well tolerated in adults. The efficacy of the HEV 239 vaccine against symptomatic and asymptomatic infection had been proven to be high during a Phase III clinical trial and long-term follow up. The safety and efficacy of HEV 239 vaccine in certain high-risk populations remains to be further investigated.

Entities:  

Keywords:  HEV 239; Hecolin; Hepatitis E virus; efficacy; vaccine

Mesh：

Substances：

Year:  2015        PMID： 25714510      PMCID： PMC4514148          DOI： 10.1080/21645515.2015.1008870

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  40 in total

1.  In-depth process understanding of RECOMBIVAX HB® maturation and potential epitope improvements with redox treatment: multifaceted biochemical and immunochemical characterization.

Authors:  Qinjian Zhao; Victoria Towne; Martha Brown; Yang Wang; Dicky Abraham; C Brent Oswald; Juan A Gimenez; Michael W Washabaugh; Ronald Kennedy; Robert D Sitrin
Journal:  Vaccine       Date:  2011-08-25       Impact factor: 3.641

2.  Structural basis for the neutralization and genotype specificity of hepatitis E virus.

Authors:  Xuhua Tang; Chunyan Yang; Ying Gu; Cuiling Song; Xiao Zhang; Yingbin Wang; Jun Zhang; Choy Leong Hew; Shaowei Li; Ningshao Xia; J Sivaraman
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-03       Impact factor: 11.205

3.  A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates.

Authors:  Shao W Li; Jun Zhang; Yi M Li; Shan H Ou; Guo Y Huang; Zhi Q He; Sheng X Ge; Yang L Xian; Shu Q Pang; Mun H Ng; Ning S Xia
Journal:  Vaccine       Date:  2005-04-22       Impact factor: 3.641

4.  Safety and efficacy of a recombinant hepatitis E vaccine.

Authors:  Mrigendra Prasad Shrestha; Robert McNair Scott; Durga Man Joshi; Mammen P Mammen; Gyan Bahadur Thapa; Narbada Thapa; Khin Saw Aye Myint; Marc Fourneau; Robert A Kuschner; Sanjaya Kumar Shrestha; Marie Pierre David; Jitvimol Seriwatana; David W Vaughn; Assad Safary; Timothy P Endy; Bruce L Innis
Journal:  N Engl J Med       Date:  2007-03-01       Impact factor: 91.245

5.  Hepatitis E vaccine development: a 14 year odyssey.

Authors:  Ting Wu; Shao-Wei Li; Jun Zhang; Mun-Hon Ng; Ning-Shao Xia; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2012-06-01       Impact factor: 3.452

6.  Hepatitis E virus capsid protein assembles in 4M urea in the presence of salts.

Authors:  Chunyan Yang; Huirong Pan; Minxi Wei; Xiao Zhang; Nan Wang; Ying Gu; Hailian Du; Jun Zhang; Shaowei Li; Ningshao Xia
Journal:  Protein Sci       Date:  2013-01-17       Impact factor: 6.725

Review 7.  Development of the hepatitis E vaccine: from bench to field.

Authors:  Jun Zhang; James WaiKuo Shih; Ting Wu; Shao-Wei Li; Ning-Shao Xia
Journal:  Semin Liver Dis       Date:  2013-04-05       Impact factor: 6.115

Review 8.  Antigenic determinants of hepatitis E virus and vaccine-induced immunogenicity and efficacy.

Authors:  Qinjian Zhao; Jun Zhang; Ting Wu; Shao-Wei Li; Mun-Hon Ng; Ning-Shao Xia; James Wai-Kuo Shih
Journal:  J Gastroenterol       Date:  2012-11-13       Impact factor: 7.527

9.  Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity.

Authors:  Qinjian Zhao; Yorgo Modis; Katrina High; Victoria Towne; Yuan Meng; Yang Wang; Jaime Alexandroff; Martha Brown; Bridget Carragher; Clinton S Potter; Dicky Abraham; Dave Wohlpart; Mike Kosinski; Mike W Washabaugh; Robert D Sitrin
Journal:  Virol J       Date:  2012-02-22       Impact factor: 4.099

10.  Hepatitis e vaccine to prevent morbidity and mortality during epidemics.

Authors:  Kenrad E Nelson; James W K Shih; Jun Zhang; Qinjian Zhao; Ningshao Xia; John R Ticehurst; Alain B Labrique
Journal:  Open Forum Infect Dis       Date:  2014-11-04       Impact factor: 3.835
View more
  34 in total

Review 1.  Development of new hepatitis E vaccines.

Authors:  Yufeng Cao; Zhenhong Bing; Shiyu Guan; Zecai Zhang; Xinping Wang
Journal:  Hum Vaccin Immunother       Date:  2018-06-18       Impact factor: 3.452

2.  A preliminary cost-effectiveness analysis of hepatitis E vaccination among pregnant women in epidemic regions.

Authors:  Yueyuan Zhao; Xuefeng Zhang; Fengcai Zhu; Hui Jin; Bei Wang
Journal:  Hum Vaccin Immunother       Date:  2016-02-22       Impact factor: 3.452

3.  Health economic evaluation of immunization strategies of hepatitis E vaccine for elderly population.

Authors:  Xiaoqing Cheng; Yueyuan Zhao; Xuefeng Zhang; Hui Jin; Jie Min
Journal:  Hum Vaccin Immunother       Date:  2017-04-27       Impact factor: 3.452

4.  Immunogenicity and protective efficacy of an EV71 virus-like particle vaccine against lethal challenge in newborn mice.

Authors:  Shiyang Sun; Fan Gao; Qunying Mao; Jie Shao; Liping Jiang; Dawei Liu; Yiping Wang; Xin Yao; Xing Wu; Bo Sun; Dandan Zhao; Youlei Ma; Jingcai Lu; Wei Kong; Chunlai Jiang; Zhenglun Liang
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 5.  Approved Antiviral Drugs over the Past 50 Years.

Authors:  Erik De Clercq; Guangdi Li
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

6.  Effect of freezing on recombinant hepatitis E vaccine.

Authors:  Kelei Li; Fangyu Dong; Fan Gao; Lianlian Bian; Shiyang Sun; Ruixiao Du; Yalin Hu; Qunying Mao; Haifa Zheng; Xing Wu; Zhenglun Liang
Journal:  Hum Vaccin Immunother       Date:  2019-12-06       Impact factor: 3.452

7.  Functional epitopes on hepatitis E virions and recombinant capsids are highly conformation-dependent.

Authors:  Bin He; Zhigang Zhang; Xinyuan Zhang; Zimin Tang; Chang Liu; Zizheng Zheng; Shaowei Li; Jun Zhang; Ningshao Xia; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2020-01-29       Impact factor: 3.452

Review 8.  Viral hepatitis and pregnancy.

Authors:  Norah A Terrault; Miriam T Levy; Ka Wang Cheung; Gonzague Jourdain
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-10-12       Impact factor: 46.802

9.  Phage-displayed peptides that mimic epitopes of hepatitis E virus capsid.

Authors:  Osmany Larralde; Juraj Petrik
Journal:  Med Microbiol Immunol       Date:  2017-04-22       Impact factor: 3.402

10.  Epidemiology, diagnosis, vaccines, and bibliometric analysis of the 100 top-cited studies on Hepatitis E virus.

Authors:  Tauseef Ahmad; Saima Nasir; Taha Hussein Musa; Saif Aldeen S AlRyalat; Muhammad Khan; Jin Hui
Journal:  Hum Vaccin Immunother       Date:  2020-08-05       Impact factor: 3.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.